Get to know our clinical trials

Multicenter, open-label, single-arm, multicenter phase II clinical trial to evaluate the efficacy of axicabtagene ciloleucel in patients with late relapsed diffuse large B-cell lymphoma

THE AIM OF THE STUDY IS TO EVALUATE THE EFFICACY OF THE STUDY TREATMENT, AXICABTAGENE CILOLEUCEL, WHEN ADMINISTERED TO PATIENTS WITH AGGRESSIVE BGCL AS A SECOND LINE (MEANING THAT THE PATIENT MUST HAVE RECEIVED ANOTHER TREATMENT BEFORE).

Imagen del Dr. Miguel Ángel Canales Albendea, especialista en Hematología y Hemoterapia de la Clínica Universidad de Navarra. El Dr. Canales se dedica preferencialmente al estudio y tratamiento de los linfomas y procesos linfoproliferativos.
Dr. Miguel Ángel Canales Albendea Curriculum
Specialist Hematology and Hemotherapy Department
Navarre headquarters
Madrid headquarters
Cancer Center
Hematologic Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase

Technical Summary

  • MULTICENTER, OPEN-LABEL, SINGLE TREATMENT ARM PHASE II STUDY TO EVALUATE THE EFFICACY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH LATE RELAPSE OF DIFFUSE LARGE B CELL LYMPHOMA
  • Code EudraCT: 2024-512835-53-00
  • Protocol number: LATE-R-GEL-23
  • Promoter: Fundación GELTAMO
  • Molecule/Drug: Axicabtagene ciloleucel

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION